OMIP-050: A 28-color/30-parameter Fluorescence Flow Cytometry Panel to Enumerate and Characterize Cells Expressing a Wide Array of Immune Checkpoint Molecules

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

CD103 and Intratumoral Immune Response in Breast Cancer

(2016) Z.-Q. Wang et al.   CLINICAL CANCER RESEARCH

OMIP-037: 16-color panel to measure inhibitory receptor signatures from multiple human immune cell subsets

(2016) Anna C. Belkina et al.   CYTOMETRY PART A

OMIP-036: Co-inhibitory receptor (immune checkpoint) expression analysis in human T cell subsets

(2016) Zachary R. Healy et al.   CYTOMETRY PART A

OMIP-031: Immunologic checkpoint expression on murine effector and memory T-cell subsets

(2016) Satoshi Nemoto et al.   CYTOMETRY PART A

Rationale for anti-GITR cancer immunotherapy

(2016) Deborah A. Knee et al.   EUROPEAN JOURNAL OF CANCER

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

(2014) Xiaozhou Fan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

(2013) P. A. Ott et al.   CLINICAL CANCER RESEARCH

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors

(2011) S. F. Ngiow et al.   CANCER RESEARCH

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

(2011) Marie Tosolini et al.   CANCER RESEARCH